Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) EBT Margin (2020 - 2025)

Bioventus' EBT Margin history spans 6 years, with the latest figure at 8.96% for Q4 2025.

  • For Q4 2025, EBT Margin rose 899.0% year-over-year to 8.96%; the TTM value through Dec 2025 reached 4.53%, up 1366.0%, while the annual FY2025 figure was 4.53%, 1366.0% up from the prior year.
  • EBT Margin reached 8.96% in Q4 2025 per BVS's latest filing, up from 3.37% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 29.9% in Q2 2021 to a low of 101.47% in Q4 2022.
  • Average EBT Margin over 5 years is 12.56%, with a median of 4.01% recorded in 2024.
  • Peak YoY movement for EBT Margin: plummeted -9858bps in 2022, then soared 9469bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 2.11% in 2021, then crashed by -1123bps to 25.78% in 2022, then soared by 76bps to 6.21% in 2023, then surged by 99bps to 0.03% in 2024, then surged by 26065bps to 8.96% in 2025.
  • Per Business Quant, the three most recent readings for BVS's EBT Margin are 8.96% (Q4 2025), 3.37% (Q3 2025), and 6.98% (Q2 2025).